Drugs / Soy Isoflavone
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05667701 | Sep 2024 → Mar 2028 expected | childhood onset asthma | Rajesh Kumar | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00235924 | Jun 2004 → ? | — | Laboratoires Arkopharma | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00262184 | Dec 2004 → Dec 2007 | postmenopausal osteoporosis | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soy Isoflavone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00262184 ↗ |
| Route | Oral | “oral administration of 300 mg isoflavone aglycone/day or placebo” NCT00262184 ↗ |